← Back to Clinical Trials
Recruiting NCT03629418

Targeted Blood-pressure Management and Acute Kidney Injury After Coronary Artery Bypass Surgery

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Coronary Artery Bypass, Off-Pump
Sponsor Peking University First Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 612
Sex ALL
Min Age 50 Years
Max Age N/A
Start Date 2018-08-14
Completion 2025-12
Interventions
Targeted blood-pressure managementRoutine blood-pressure management

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Acute renal injury (AKI) is a common complication after cardiac surgery and is associated with worse outcomes. It is now realized that intraoperative hypotension is an important risk factor for the development of AKI. In a recent randomized controlled trial of patients undergoing major noncardiac surgery, intraoperative individualized blood-pressure management reduced the incidence of postoperative organ dysfunction. The investigators hypothesize that, for patients undergoing off-pump CABG, targeted blood-pressure management during surgery may also reduce the incidence of postoperative AKI.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 50 years; * Scheduled to undergo off-pump CABG surgery. Exclusion Criteria: * Refuse to participate; * Untreated or uncontrolled severe hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg); * Chronic kidney disease with a glomerular filtration rate \< 30 ml/min/1.73 m2 or end-stage renal disease requiring renal-replacement therapy; * Inability to communicate during the preoperative period because of coma, profound dementia, language barrier, or end-stage disease; * Requirement of vasopressors/inotropics to maintain blood pressure before surgery; * Second or emergency surgery; * Expected survival of less than 24 hours.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}